Abstract The association between beta human papillomavirus (HPV) types and cutaneous squamous cell carcinomas (cSCCs) is controversial. Several studies have found such an association, especially at early stages of carcinogenesis, but the presence of beta HPV types in aggressive cSCCs has only been reported in three patients previously. We aimed to search for beta HPV DNA in primary cSCCs and their corresponding lymph node metastases in a series of patients. The presence of DNA from 25 beta HPV types was determined using a multiplex PCR protocol in 35 primary cSCCs from 35 patients and their corresponding lymph node metastases. DNA from beta HPV types was detected in 9 % of primary cSCCs and in 13 % of metastases. No primary cutaneous SCC or lymphatic metastases were found to share the same HPV DNA. These data suggest that beta HPV types do not play an etiopathogenic role in advanced stages of squamous cell carcinogenesis.
Introduction
Mucosal high-risk (HR) human papillomavirus (HPV) types, e.g. HPV16, have been clearly associated with cervical cancer, other anogenital carcinomas and oropharyngeal cancers. In addition, the skin HPV types that belong to the genus beta of the HPV phylogenetic tree are suspected to play a role in the development of non-melanoma skin cancer (NMSC) [7] . Beta HPV types, e.g. HPV5 and 8, were first identified in individuals suffering from a genetic disorder called epidermodysplasia verruciformis (EV) [9] . Beta HPV types are highly ubiquitous in the normal population and, according to some authors, might also play a role in skin carcinogenesis in non-EV individuals [1] . In addition, impairment of the immune system in organ transplant recipients, which may favour viral infections, strongly increases the risk of developing NMSC [2] .
Functional studies in in vitro and in vivo experimental models have highlighted the oncogenic properties of beta HPV types [14, 15] . However, analyses of NMSC specimens have not revealed the presence of viral transcripts [5] . In addition, the use of quantitative, type-specific PCR has shown that far \1 copy of HPV DNA per cell is present in NMSC specimens [16] . This scenario differs from that observed in cervical cancers, where at least one copy of mucosal HR HPV DNA is detected in each cancer cell [12] .
Together, these findings suggest that beta HPV may play a role only at an initial stage of skin carcinogenesis.
HPV16 detection in lymphatic metastases has been found to be concordant with that found in the corresponding primary oropharyngeal squamous cell carcinomas and may aid in finding the primary tumour in patients with cervical lymph node metastases of unknown origin [3] . A few small case series have addressed the study of beta HPV in primary cutaneous squamous cell carcinoma (cSCC) and their corresponding metastases [10, 11] . Ostrow et al. demonstrated the presence of HPV5 DNA in a cSCC and its subcutaneous metastasis in a patient with EV [11] . Nindl et al. observed the presence of identical HPV14, 21, and/or 36 variants in paired primary and metastatic tumours in two patients [10] .
To further characterise the role of beta HPV types in skin carcinogenesis, we have determined the presence of viral DNA in cSCCs and their corresponding lymph node metastases. In case that HPV played a role in the induction of lymphatic metastases, one should expect to find HPV DNA in both types of lesions.
Methods
Records from the Pathology Departments of three hospitals in Barcelona, Spain (Hospital del Mar, Hospital Universitari de Bellvitge and Hospital Vall d 0 Hebron) were retrospectively searched to identify patients with cSCC who had developed metastatic spread between 2001 and 2011. Only those patients from whom both biopsy specimens (the primary tumour and metastases) were available were included in the study.
Approval to conduct this study was obtained from the ethics committees of all the centres participating in the study, and in accordance with the guidelines of the Helsinki Declaration of 1975, as revised in 1983.
We determined the presence of DNA from 25 beta HPV types, namely HPV5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 93, and 96, using a multiplex PCR protocol combined with a Luminex-based assay, as previously reported [6] .
Results
Thirty-five patients with primary cSCC who developed regional lymph node metastases were identified. Seventy paraffin-embedded samples, from 35 primary tumours and their corresponding lymph node metastases were retrieved. The mean age of the patients was 77, 25 years (range 46-95) and 74.3 % were men. Three of the 35 patients were immunosuppressed, and five of the skin tumours were from non-sun-exposed anatomical sites. The clinico-pathological features of the evaluated patients are illustrated in Table 1. For the primary tumours, three DNA samples were found to be beta-globin negative and were excluded from the study. Of the 32 remaining cSCCs, only three (9.3 %) were positive for a single beta HPV infection, i.e. HPV22, 24, and 75. None of the corresponding metastases associated to these cases showed HPV positivity. All three beta HPV positive cases were from sunexposed anatomical sites in non-immunosuppressed patients.
For the lymph node metastases, four specimens were found to be beta-globin negative and were not further analysed. Of the 31 remaining lymphatic metastases, four (13 %) were positive for a single beta HPV type, i.e. HPV5 (detected in two samples), 24, and 75. None of these cases showed HPV positivity in their corresponding primary cSCC. 
Discussion
The prevalence of HPV DNA in NMSC from immunocompetent patients has been reported to range between 13 and 84 % [1] . Surprisingly, in this study beta HPV DNA was detected at a low rate, although a very sensitive assay was used for the detection of viral DNA. Beta HPV types may not be involved in NMSC, although such a conclusion is not in agreement with initial epidemiological studies, which consistently show a moderate positive association between HPV infection and a history of NMSC [1, 4, 8] .
Moreover, we cannot exclude the possibility that metastatic cSCCs harbour lower HPV infection rates than nonmetastatic tumours. Independent studies have shown that beta HPV prevalence is higher in the precursor lesion, or actinic keratosis, than in the invasive cSCC, suggesting that the virus may play a role at early stages of carcinogenesis [13, 16] . Since it is well demonstrated that beta HPV E6 and E7 oncoproteins inhibit the DNA repair machineries, it is likely that beta HPV types facilitate the accumulation of ultraviolet-mediated DNA damage at early stages of tumour development and could be lost in invasive stages [16] . In this sense, Weissenborn et al. found that the HPV DNA load was undetectable by Q-PCR in eight metastases of cSCCs [16] . Moreover, our series mostly includes immunocompetent patients, which may harbour less HPVassociated cSCCs than immunosuppressed individuals.
Quite surprisingly, we found HPV in four metastases in whose primary tumours no HPV DNA was detected. This may either reflect a technical limitation (false negative in primary tumours or false positive in the metastases) or a clonal selection. In any case, the latter scenario would seem clinically irrelevant in light of the few cases of metastases showing HPV positivity.
Our study has some limitations, which should be stated. This was a retrospective study, with a small series. In addition, we did not compare our results with a nonmetastasizing series of tumours.
In conclusion, irrespective of their hypothetical role in inducing epithelial malignancy in skin, beta HPV types do not appear to play a role in the maintenance of the malignant phenotype in advanced cSCC.
